Buprofezin not renewed: an endocrine disruptor for the thyroid in humans, consumer risk assessment for residues in honey and rotational crops not finalised; authorisations withdrawn by 3 June 2027, use of stocks until 3 December 2027
Commission Implementing Regulation (EU) 2026/2517, published on 13 November 2026, does not renew the approval of the active substance buprofezin and deletes it from Part A of the Annex to Implementing Regulation (EU) No 540/2011. The Commission relies on the EFSA conclusions of 16 April 2025: buprofezin meets the criteria for an endocrine disruptor with regard to the thyroid hormone modality in humans.
- EFSA concerns listed in the act: it was not demonstrated that human exposure to buprofezin in a plant protection product under realistic conditions of use is negligible; owing to a lack of data, the endocrine-disrupting properties could not be assessed for non-target organisms other than mammals.
- Owing to a lack of appropriate data, the consumer risk assessment taking into account potential residues in honey and rotational crops, the risk assessment for bees and other non-target arthropods for use in temporary greenhouses and the risk assessment for aquatic organisms could not be finalised. The applicant’s comments did not alleviate the Commission’s concerns.
- Deadlines: Member States withdraw authorisations for plant protection products containing buprofezin by 3 June 2027, and the grace period for using up stocks expires on 3 December 2027 at the latest. The approval, extended by Implementing Regulation (EU) 2026/2348 to 15 March 2027, according to recital 17 the new act applies before that date.
- Course of the assessment: the rapporteur Member State was Italy and the co-rapporteur Austria; the draft renewal assessment report was submitted to EFSA on 9 September 2021 with a proposal to renew. Buprofezin was included as an active substance by Commission Directive 2011/6/EU.
- The Regulation enters into force on the twentieth day following its publication (3 December 2026). The act only amends the list of approved active substances (Implementing Regulation (EU) No 540/2011) and does not concern maximum residue levels; the decision is based on the EFSA conclusions (EFSA Journal 2025; 23(4):9392).